Manish Sahni, MD Table of Contents: What are the expected benefits of using Semaglutide GLP-1 for weight management
Also, strategic collaborations, clinical trials, and higher spending on metabolic disorder research keep backing long-term expansion and further technological advancement inside the market
Demand for GLP-1 Receptor Agonists in China Based on data released by the Chinese government, 141 million Chinese suffer from diabetes , with the figure expected to increase to 174.4 million in 2045
BMI Over 35 No additional questions
In 2025, the company delivered a strong +19.93% YoY revenue growth, driven by its immunology leadership: Dupixent ($18.48B) continues to be the primary growth engine with expanding indications and global uptake, while Lantus ($2.03B) and Toujeo ($1.58B) remain important contributors in diabetes, albeit facing competitive and pricing pressures reflecting a clear transition toward specialty medicines
On its website, the company points to a study that found people taking 1 milligram of semaglutide, less than half of the maximum dose, lost an average of 16% of their body weight over 64 weeks
